Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
atomoxetin actavis hart hylki 18 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 18 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
atomoxetin actavis hart hylki 25 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 25 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
atomoxetin actavis hart hylki 40 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 40 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
atomoxetin actavis hart hylki 60 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 60 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
atomoxetin actavis hart hylki 80 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 80 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
gabapentin alvogen (gabapentin ratiopharm) hart hylki 300 mg
alvogen ehf. - gabapentinum inn - hart hylki - 300 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - Önnur hjartablöndur - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.